For biotechs meeting with current and potential investors, says Edward Ahn, CEO, Medipost Inc., “it should be about demonstrating your business continuity more than anything else.” Investors know, he says, “any supply chain may be fragile.” Indeed, Ahn’s organization has put in place an intriguing business model to address such concerns. It includes owning part of a CDMO.
- The Real Reason We Haven't Fully Automated Cell Therapy Yet
- The Hidden Engineering Behind Successful Upstream Bioprocessing
- A Practical Look At Modern Downstream Processing For Biologics
- Process Engineering's Key Role In Sterile Injectable Facility Design
- What To Know About — And How To Apply For — FDA's PreCheck Pilot
- MES Is Still In The CD ROM Era But The Data Architecture Has Moved On
- A Novel In Vitro Glycosylation Approach For Difficult PTMs
EDITOR'S DESK
-
We're A Virtual Biotech. CDMOs Should Treat Us As A Priority
Chief Editor Louis Garguilo says he's sure some readers will smirk at our headline. CDMOs are running a business; they may attempt to treat all customers equally, but they focus where the most financial gain is. That's usually with bigger clients. Nonetheless, according to a very experienced outsourcing professional, there's nothing humorous here at all.
New FDA draft guidance aims to reduce the timeline and cost of developing biosimilars.
Experts discuss innovation in antibody-drug conjugate (ADC) technology and how these impact CMC strategy. This summary captures key takeaways from the Bioprocess Online Live event "Evolving CMC Strategies To Enable Next-Gen ADCs."
Capacity isn’t the choke point—capability is; this piece ranks nine fast-growing outsourcing segments and shows sponsors how to win by locking in modality-proven partners early.
At BioProcess International 2025, leaders from AbbVie and Amgen gave keynote presentations about how their companies are advancing product development through digital tools.
GUEST COLUMNISTS
-
The Hidden Engineering Behind Successful Upstream Bioprocessing
In upstream biopharmaceutical production, manufacturing is inseparable from biology, engineering, contamination control, and quality science.
-
A Practical Look At Modern Downstream Processing For Biologics
Part 2 in a series about current bioprocessing practices explores the latest in separation, purification, sterile filtration and aseptic filling.
-
Process Engineering's Key Role In Sterile Injectable Facility Design
Quality requirements for parenteral drugs complicate facility design like few other regulated products. If you're developing injectables, be aware of these key issues.
-
What To Know About — And How To Apply For — FDA's PreCheck Pilot
FDA has now provided specific eligibility and selection criteria for the PreCheck Pilot Program and a timeline for next steps.
-
MES Is Still In The CD ROM Era But The Data Architecture Has Moved On
Many manufacturing execution system (MES) deployments still operate like it is 2005: a big install, disruptive upgrades, etc. Here's a clearer path forward.
-
A Novel In Vitro Glycosylation Approach For Difficult PTMs
Post-translational modifications of membrane proteins have been historically challenging. Research shows how an in vitro approach brings stability and predictability.
-
Field Notes: Reducing Risk At Kivi Bio's Interchangeability Conference
Risk and fitness for use of interchangeable single-use parts were key themes at the conference. The event exposed communication gaps between suppliers and end-users.
-
Using Carbon Nanotubes To Pinpoint Optimal Harvest Time in Bioprocessing
Cell-free expression systems confound the moment of peak expression. These nanosensors signal through crude lysate for process optimization and endpoint monitoring.
BIOPROCESSING WHITE PAPERS
-
Maximize Your Laboratory Efficiency
Gain insight into how labs can boost productivity by reducing downtime, minimizing errors, and increasing walk-away time through real-time insights and analytics.
-
Producing MSC-Derived Cell Therapies From Isolation To Large-Scale Expansion8/4/2025
Explore the journey of producing MSC-derived cell therapies, from initial isolation and expansion to final product formulation and storage, and learn how to optimize each step.
-
How Automation Is Driving Carbon Reduction10/21/2025
Manufacturers can cut emissions and boost efficiency by modernizing energy and utility systems. Explore how smart automation and analytics offer fast ROI and long-term sustainability.
-
A Journey To Boundless Automation In Life Sciences7/1/2025
Boundless automation reimagines industrial computing through seamless integration of the intelligent field, edge, and cloud, unified by a real-time data fabric that enables digital transformation.
-
The GxP Digital Maturity Model8/8/2025
Explore how the GMP Digital Maturity Model guides life sciences companies through five stages to improve compliance, efficiency, and profitability with strategic digital adoption.
-
Onshoring Advantage: 7 Forces Reshaping Global Biologics Manufacturing10/27/2025
Policy, trade, and security pressures are fundamentally reshaping global biologics manufacturing. Forward-looking companies are onshoring critical programs to mitigate risks to supply chains, IP, and regulatory timelines.
BIOPROCESSING APP NOTES & CASE STUDIES
- Overcoming Bispecific Antibody Purification Challenges
- Optimize T Cell Phenotype With One-Step Isolation And Activation
- Antibody Coverage Analysis Of E. coli HCPs In The BL21(DE3) Strain
- Cytokine-Mediated Inflammation In A Relevant Preclinical Model
- Assessment Of Compound Toxicity Effects With High-Content Imaging
- Taking The First Steps Towards Digitalizing Biopharma Development
- Bioprocess Online's 2025 Editorial Reflections
- FDA Releases Draft Guidance To Accelerate Biosimilar Development
- Supporting The Next Generation Of ADCs
- AbbVie And Amgen's Blueprint To Digitalize Biomanufacturing
- On The Ground At BPI: Kat Kozyrytska On Ethical AI And Collaboration
- On The Ground At BPI: Takeda's Amy Shaw On Scaling Cell Therapy Manufacturing
BIOPROCESS ONLINE CONTENT COLLECTIONS
This collection of articles digs into the industry’s growing focus on knowledge management as an indispensable facet of biomanufacturing and pharmaceutical development, exploring how it plays into risk management, quality, vendor relationships, and supply chain resilience.
More Content CollectionsFEATURED PRODUCTS AND SERVICES
ON-DEMAND WEBINARS
- USP <665> Compliance Guidance
- Practical Considerations For Aseptic Gowning In Contamination Control Strategies
- Optimizing Antibody Variant Capture: Strategies To Combat Aggregation, Impurities, And Low Yields
- Integrated Thinking for Complex FIH Programs
- Four Common Pitfalls To Avoid In UF/DF Setup And Scale-Up
INDUSTRY NEWS
NEWSLETTER ARCHIVE
- 03.04.26 -- A Novel In Vitro Glycosylation Approach For Difficult PTMs
- 03.03.26 -- Driving Fill-Finish Flexibility
- 03.03.26 -- The U.S. Has A New Vice To Squeeze Foreign Imports: Pharma Quality
- 03.02.26 -- Advanced Fluid Management Solutions For Drug Substance Handling
- 03.02.26 -- Using Carbon Nanotubes To Pinpoint Optimal Harvest Time In Bioprocessing